Sign in
CompletedNo phase

Creatine Monohydrate for Mild Traumatic Brain Injury: a Randomised Controlled Pilot Study

Key facts

Who runs it
University of Southern Denmark
Where
Denmark1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
34 people enrolled
Started
1 Aug 2023
Ended
31 Dec 2024
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Creatine Monohydrate
  • Sugar Pill (Placebo)
Record updated
7 April 2026

Who can take part

Age
20 years to 45 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • The time since concussion was 6-18 months
  • The age range was 20-45 years
  • Only participants who had not initiated any new pharmacological or non-pharmacological treatments from three weeks prior to inclusion until study completion were eligible

Who cannot take part

  • Moderat to high level of intensity for no more than 10 hours per week
  • Pregnant

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Objectives: Approximately one-third of patients with concussion experience persistent symptoms that, in addition to causing serious discomfort, may lead to unemployment and other socioeconomic challenges. Animal studies suggest that creatine monohydrate may alleviate post-concussive symptoms. This pilot study investigated the effects of creatine monohydrate on post-concussive symptoms in humans and assessed the feasibility of the pilot trial.

Read full original descriptionShow less

Design: Three-arm randomised controlled pilot trial (intervention, placebo, control).

Setting: Participants were recruited through neurological outpatient clinics and public outreach in Denmark.

Participants: The study included 34 participants aged 20-45 years who had been experiencing persistent post-concussive symptoms for 6-18 months since injury. Participants were randomised to one of three groups.

Intervention: The intervention group received 5 g of creatine monohydrate daily for seven weeks. The placebo group received an identical inert powder following the same regimen. The control group received usual care only.

Primary and secondary outcome measures: The primary outcome was post-concussion symptoms (Rivermead Post Concussion Symptoms Questionnaire (RPQ)). Secondary outcomes were acute (RPQ-3) and persistent (RPQ-13) symptoms, assessed at three time points (week 0, 4 and 8).

Results: All participants completed follow-up, indicating the trial's high feasibility and practicality. The intervention group did not significantly differ from the placebo or control groups. Moderate effect sizes were noted for RPQ-13 and total RPQ scores (d = -0.47, -0.46) and small for RPQ-3 scores (d = -0.22), although none reached statistical significance. Similar effects were observed between the placebo and control groups.

Conclusions: The study showed strong usability and practical feasibility. Effect sizes were exploratory and not indicative as evidence of treatment efficacy at this stage. Larger randomized controlled trials are needed to determine whether creatine monohydrate could be a safe, accessible adjunctive treatment for post-concussive symptoms.

The 3 groups in the trial

  • Intervention group (Creatine)Treatment being tested

    Creatine Monohydrate administered once a day for seven weeks - with 5 g/day for the entire period.

    Treatment: Creatine Monohydrate

  • Control group - No treatmentNo study treatment, for comparison

    The control group will receive standard care. However, to our knowledge there is no common accepted description of standard care in the literature. In general, these participants will be advised to keep as asymptomatic as possible throughout seven weeks, and live as normal as possible.

  • Placebo group (Sugar pill)Placebo, for comparison

    Powdered sugar administered once a day for seven weeks - with 5 gram/day for the entire period.

    Treatment: Sugar Pill (Placebo)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
7 April 2026